



JOINT WORKING EXECUTIVE SUMMARY

Project Title: Lung Cancer pathway project (a Phase 2 project of the Somerset Cancer Programme Joint working project)

Project description:

This project aims to understand variation and where costs sit along the lung cancer pathway to identify where efficiency savings and service improvements can be made to benefit patient care.

The Somerset Cancer Programme was established by NHS England South West Clinical Network and Roche Products Ltd under the terms of a joint working agreement dated September 2016. The overall ambition of the Programme is to develop an innovative ambitious cancer care model in Somerset, using the Programme as a catalyst.

Following the completion of Phase 1 of the Programme, the Steering Group (comprised of members of the Somerset vanguard and Roche Products Limited) have identified specific priority projects that they would like to undertake as part of Phase 2 of the Programme.

Organisations involved:

Roche Products Ltd and NHS England South West Strategic Clinical Network, coordinating contributions from Yeovil NHS Foundation Trust(FT), NHS England South (South West), Taunton and Somerset NHS Foundation Trust(FT), Somerset Clinical Commissioning Group(CCG)

Project approach:

This project will map and identify costs associated with the lung cancer pathway to identify gaps in the existing service provision against national and local guidance, to assess where improvements could be made. This will include identification and understanding of patient flow and routes to lung cancer diagnosis in the Somerset locality.

Project outputs, which include a simulation model, can be used to optimise the lung cancer pathway and simulate service redesign proposals that will enable more effective resource allocation to improve service quality and patient experience.

No clinical safety or outcomes will be measured as part of this project.

Expected outcomes:

Benefits to Patients:

The project aims to identify where potential service changes and efficiency savings can be made to support improving service quality and patient experience.

Benefit to NHS:

Provide the NHS with i) feedback of service provision and opportunity to identify improvement areas and ii) an understanding of where costs sit along the lung cancer pathway and allow scenario simulation to support pathway redesign and optimisation.

Benefits to Roche:

Provide system level insights and supporting work in understanding whether lung cancer to be appropriately commissioned, with adequate funding and infrastructure for new innovative treatments as they become available. The simulation model could be used as a template to support service improvements in other NHS localities.

Resource Breakdown

Roche Products Ltd contribution to the Joint working project is £50,000 made up of consultancy costs in pathway mapping, building of the simulation model and to support publication.

The estimated NHS prorated staff contribution to the project, coordinated through the South West Strategic Clinical Network, is £47,000 but made up of contributions from Yeovil FT, NHS England South West, Taunton and Somerset FT, Somerset CCG towards a total budget of £97,000.

This document has been produced by Roche Products Ltd.

